Vical To Collaborate In DNA Vaccine Technology

22 September 1996

- Vical is to collaborate with Stanford University Medical Center in California, USA, in the development of a DNA protective vaccine against beta-cell lymphoma. The vaccine uses "naked" DNA technology from Vical to deliver a gene that causes muscle cells to produce idiotypic determinant which targets tumor cells. The immune defenses would then produce anti-Id antibodies and T-cells that would eliminate the rest of the tumor cells and prevent relapse. The results of the preclinical study are presented in Nature Medicine (September 2).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight